Bioscience Ventures

Bioscience Ventures (BSV) is a specialized healthcare and life sciences commercialization vehicle, operating as a joint venture between the investment group NetScientific and the University of Southampton. The company focuses on identifying and developing early-stage intellectual property from academic research, particularly in the fields of diagnostics and therapeutics. BSV acts as an incubator, providing the necessary funding and management expertise to transition high-potential scientific discoveries into viable commercial entities. Its portfolio has historically included interests in companies such as ProAxsis, which develops point-of-care diagnostics for chronic inflammatory airway diseases, and Glycotest, which focuses on liver disease diagnostics. By bridging the gap between academia and industry, Bioscience Ventures plays a critical role in the translation of innovative medical research into clinical applications.